Effectiveness of mRNA-1345 vaccine in preventing RSV-associated lower respiratory tract disease
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 31st, 2024
|
The existing vaccines designed to protect against respiratory syncytial virus (RSV) leverage the pre-fusion glycoprotein F (preF) as the primary antigen, demonstrating their efficacy. Moderna, a pharmaceutical company, has recently employed mRNA technology, previously utilized for the SARS-CoV-2 vaccine, to generate RSV protein. The results of a study evaluating the effectiveness of an RSV preF mRNA vaccine have been published in the New England Journal of Medicine.
The research involved the enrollment of 35,541 participants, averaging 68.1 years of age, with 5.5% of them having chronic obstructive pulmonary disorder. These participants were randomly assigned to two groups: one receiving the vaccine containing 50 micrograms of mRNA-1345, and the other receiving a placebo in the form of saline. After a median follow-up period of 112 days, the study determined that the mRNA-1345 vaccine exhibited an efficacy of 83.7% in preventing lower respiratory tract disease associated with RSV. Notably, the vaccine showed higher efficacy against RSV subtype A compared to subtype B. The majority of reported adverse events were mild and transient, with injection-site pain and fatigue being the most commonly reported side effects.
The research involved the enrollment of 35,541 participants, averaging 68.1 years of age, with 5.5% of them having chronic obstructive pulmonary disorder. These participants were randomly assigned to two groups: one receiving the vaccine containing 50 micrograms of mRNA-1345, and the other receiving a placebo in the form of saline. After a median follow-up period of 112 days, the study determined that the mRNA-1345 vaccine exhibited an efficacy of 83.7% in preventing lower respiratory tract disease associated with RSV. Notably, the vaccine showed higher efficacy against RSV subtype A compared to subtype B. The majority of reported adverse events were mild and transient, with injection-site pain and fatigue being the most commonly reported side effects.